Key result
Peritoneal dialysis for ultrafiltration achieves 21 months median survival in advanced HF and CRS.
Why the study?
Peritoneal dialysis for ultrafiltration could be a potential therapeutic option in cardiorenal syndrome, but its long-term outcomes have not been described.
Cohort (n=198)
Yes
Peritoneal dialysis for ultrafiltration is a feasible option with high 1-year technique survival for patients with advanced heart failure and cardiorenal syndrome, though overall survival is limited by age, frailty, and cardiac burden.
Answers are grounded in this paper and cite their sources.
Supports PD feasibility for ultrafiltration in advanced HF-CRS; leaves open survival benefit versus alternatives in frail elderly.
BACKGROUND: Heart failure (HF) prevalence is increasing, and its prognosis worsens in the presence of other comorbidities. Up to 70% of patients develop cardiorenal syndrome (CRS), which is associated with diuretic resistance or kidney deterioration over time. Peritoneal dialysis (PD) for ultrafiltration (PD-UF) could be a potential therapeutic option in CRS, although its long-term outcomes have not been described. METHODS: Retrospective registry study of the Catalan Renal Registry on patients with PD-UF indication between 2013 and 2022. Baseline clinical characteristics and follow-up until December/2022 was studied. RESULTS: Of the 1,874 incident patients on PD, 198 (10.6%) were PD-UF, 73.2% of the patients were male, and the mean age was 70.7 ± 9.3 years. Median estimated glomerular filtration rate (eGFR) at start was 22.6 (IQR: 14.8-32.8) mL/min×1.73 m2 and 75.0% have an eGFR above 15 mL/min×1.73 m2. Previous history of ischemic heart disease, arrhythmia, or cardiac surgery was recorded, and 57.6% of patients had ≥2 of these pathologies. The most common HF etiology was ischemic heart disease in 21.7% of patients. Median overall patient survival was 21 (IQR: 17.3-24.3) months. Technique survival at 1 year was 94.8%, and 27 patients were transferred to other renal replacement therapy (hemodialysis or kidney transplantation). In the Cox multivariate analysis, age ≥75 years (HR: 1.76 [95% CI: 1.20-2.59]), mild frailty (HR: 2.18 [95% CI: 1.17-2.59]), severe frailty (HR: 17.62 [95% CI: 1.20-55.48]), and the burden of cardiac disease (2 categories HR: 2.17 [95% CI: 1.05-4.47]; 3 categories HR: 2.26 [95% CI: 1.05-4.89]) were associated with poor overall survival. Technique survival was associated with eGFR (<30 mL/min×1.73 m2 HR: 5.64 [95% CI: 1.32-24.18]) and body mass index (<20 kg/m2 HR: 6.53 [95% CI: 1.06-40.12]) at baseline. CONCLUSION: PD-UF is a feasible option in patients with advanced HF and CRS. The complexity of this population increases with older age, frailty, and higher cardiac burden.
No takes yet. Share an insight, caveat, or question.
Núñez-Delgado et al. (2025) conducted a cohort in Heart failure and cardiorenal syndrome (n=198). Peritoneal dialysis for ultrafiltration (PD-UF) was evaluated on Overall patient survival. Peritoneal dialysis for ultrafiltration in patients with advanced heart failure and cardiorenal syndrome resulted in a median overall survival of 21 months and a 1-year technique survival of 94.8%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: